Ticker

Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) posted a 17% gain in 2025, but that masks the real story.

Amplify Seymour Cannabis ETF (CNBS) is positioned for upside as U.S. cannabis reclassification to Schedule III appears likely, marking a key industry milestone. CNBS exhibits extreme volatility, warranting only a small (1-3%) portfolio allocation; call options are not attractive due to high premiums. Current CNBS valuations—12x trailing earnings and 3x sales—are reasonable for a growth sector anticipating regulatory…

CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.

I recommend buying cannabis sector ETFs. Recent news suggests imminent U.S. regulatory easing, potentially reclassifying marijuana and unlocking significant sector value. Current MJ ETF price/sales is 1.5x; I conservatively project a move to 2.5x, implying 66% upside. Key risks include regulatory uncertainty, sector profitability challenges, and historical underperformance post-IPOs.

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.